PMID- 23226370 OWN - NLM STAT- MEDLINE DCOM- 20130523 LR - 20211021 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 7 IP - 11 DP - 2012 TI - Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PG - e50739 LID - 10.1371/journal.pone.0050739 [doi] LID - e50739 AB - BACKGROUND: Although the clinical outcome of acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM) is well established to be worse than for non-diabetic patients, the reasons for this remain unclear. We hypothesized that this may be related to impairment of bone marrow-derived endothelial progenitor cells (EPCs) mobilization. METHODOLOGY/PRINCIPAL FINDINGS: We observed short term bone marrow EPCs mobilization and long term clinical outcomes in 62 AMI patients with or without T2DM and investigated EPCs levels as well as bone marrow pathway changes in a rat model of diabetes after AMI. Patients with T2DM exhibited a delay (peak time diabetics vs. non-diabetics: day 7 vs. day 5) and a decrease in EPCs mobilization (diabetics vs. non-diabetics: 285+/-56/10(6) mononuclear cells (MNCs) vs. 431+/-88/10(6) MNCs, p<0.05) within one month after AMI. Plasma levels of VEGF and SDF-1alpha as well as of hsCRP were higher in T2DM patients. Over a mean of 2.26 years follow-up, T2DM patients exhibited a pronounced decrease in LVEF as well as an increase in clinical events. Glucose (HR 2.01, 95% CI 1.42-2.85, p = 0.008), first day EPC (HR 0.974, 95% CI 0.952-0.997, p = 0.02) and seven day EPCs (HR 0.966, 95% CI 0.945-0.988, p = 0.003) were independent prognostic variables for cardiovascular mortality. In a diabetic rat model of AMI, decreased circulating EPCs was accompanied by lower expression of phospho-Akt, phospho-eNOS, HIF, MMP-9 and MMP-9 activity in the bone marrow as well as impaired cardiac function, angiogenesis and increased left ventricle remodeling. CONCLUSIONS/SIGNIFICANCE: Bone marrow EPCs mobilization is delayed and reduced in diabetes, with impaired HIF/p-Akt/p-eNOS/MMP-9 signaling. This is likely to contribute to the deterioration in cardiac function and worsened clinical outcome seen in patients with T2DM. FAU - Ling, Lin AU - Ling L AD - Department of Cardiology, The Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, China. FAU - Shen, Yu AU - Shen Y FAU - Wang, Kun AU - Wang K FAU - Jiang, Chunying AU - Jiang C FAU - Fang, Chunmei AU - Fang C FAU - Ferro, Albert AU - Ferro A FAU - Kang, Lina AU - Kang L FAU - Xu, Biao AU - Xu B LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121130 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Chemokine CXCL12) RN - 0 (DAZL protein, human) RN - 0 (RNA-Binding Proteins) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Acute Disease MH - Aged MH - Animals MH - Bone Marrow Cells/pathology MH - *Cell Movement MH - Chemokine CXCL12/blood MH - Diabetes Mellitus, Type 2/*complications MH - Endothelial Cells/*pathology MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Myocardial Infarction/complications/*diagnosis/*pathology/physiopathology MH - Neovascularization, Physiologic MH - Prognosis MH - RNA-Binding Proteins/blood MH - Rats MH - Signal Transduction MH - Stem Cells/*pathology MH - Vascular Endothelial Growth Factor A/blood MH - Ventricular Dysfunction, Left/blood/complications/pathology/physiopathology MH - Ventricular Remodeling PMC - PMC3511359 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2012/12/12 06:00 MHDA- 2013/05/25 06:00 PMCR- 2012/11/30 CRDT- 2012/12/11 06:00 PHST- 2012/09/01 00:00 [received] PHST- 2012/10/24 00:00 [accepted] PHST- 2012/12/11 06:00 [entrez] PHST- 2012/12/12 06:00 [pubmed] PHST- 2013/05/25 06:00 [medline] PHST- 2012/11/30 00:00 [pmc-release] AID - PONE-D-12-26692 [pii] AID - 10.1371/journal.pone.0050739 [doi] PST - ppublish SO - PLoS One. 2012;7(11):e50739. doi: 10.1371/journal.pone.0050739. Epub 2012 Nov 30.